© 1996

Oral Antidiabetics

  • Jochen Kuhlmann
  • Walter Puls

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 119)

Table of contents

  1. Front Matter
    Pages I-XXXI
  2. Introduction

    1. J. Kuhlmann
      Pages 1-5
  3. Pathophysiology of Type 2 Diabetes Mellitus

    1. A. J. Scheen, P. J. Lefèbvre
      Pages 7-42
  4. Non-Pharmacological Management of Non-Insulin-Dependent Diabetes

  5. Sulfonylureas

    1. Front Matter
      Pages 63-63
    2. U. Panten, M. Schwanstecher, C. Schwanstecher
      Pages 129-159
    3. F. Hartig, K. H. Langer, W. Rebel, F. H. Schmidt, E. Schütz
      Pages 185-198
    4. L. Groop, G. Neugebauer
      Pages 199-259
  6. Biguanides

    1. Front Matter
      Pages 261-261
    2. N. F. Wiernsperger
      Pages 305-358
    3. F. Schmidt, F. Hartig, W. Rebel, P. Ochlich
      Pages 359-371
    4. L. S. Hermann
      Pages 373-407
  7. Glucosidase Inhibitors

    1. Front Matter
      Pages 409-409
    2. B. Junge, M. Matzke, J. Stoltefuss
      Pages 411-482
    3. H. J. Ploschke, H. Schlecker, S. Seip, C. Wünsche
      Pages 483-496

About this book


The prevalence of diabetes continues to increase worldwide. Traditionally, diabetes in its adult form has not been considered a serious life-threatening disease. This attitude needs to be changed because the complications asso­ ciated with the adult form of diabetes affect almost every organ system. The high morbidity and mortality of non-insulin-dependent diabetes mellitus (NIDDM) suggest that current treatment strategies are unsatisfactory. We therefore face an urgent need for new therapeutic approaches. When the first Handbook 0/ Oral Antidiabetics was edited by H. Maske in 1971, the risks and benefits associated with the use of oral antidiabetics were still under discussion. Nowadays, oral antidiabetics hold a strong posi­ tion in the long-term treatment of diabetes. Roughly 30% -50% of the patients with diabetes in Europe and the United States are treated with oral antidiabetics, chiefly sulfonylureas. While acknowledging the value of the ß­ cytotropic sulfonylureas, we also need to recognize important limitations of their use, e.g., in the treatment of obese diabetic patients.


Antidiabetics Biguanides Diabetes Diabetes mellitus Glucosidase inhibitors Insulin Non-Pharmacological management Pathophysiology of NIDDM Sulfonylureas antidiabetikum

Editors and affiliations

  • Jochen Kuhlmann
    • 1
  • Walter Puls
    • 2
  1. 1.Institut für Klinische PharmakologieBayer AGWuppertalGermany
  2. 2.WuppertalGermany

Bibliographic information

Industry Sectors
Health & Hospitals
Pharmacology & Toxicology
Consumer Packaged Goods